Frequency of coprescription and potential risk of bronchospasm in Colombian patients users of topical antiglaucomatous betablockers and bronchodilators

Background: Cardiovascular and respiratory effects of adrenergic agonists used in diseases like chronic obstructive pulmonary disease (COPD), and β-blockers used in glaucoma generate competitive antagonism on the same adrenergic receptor when used simultaneously with the aggravation that the β-bloc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jorge Enrique Machado-Alba, Valentina Hoyos-Soto
Formato:	article
Lenguaje:	EN
Publicado:	Universidad de Antioquia 2014
Materias:	glaucoma Pulmonary Disease Chronic Obstructive Bronchial Spasm Adrenergic beta-Antagonists Adrenergic beta-Agonists Food processing and manufacture TP368-456 Pharmaceutical industry HD9665-9675
Acceso en línea:	https://doaj.org/article/8f1ee46cf004453a97ae94b972ccb506
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8f1ee46cf004453a97ae94b972ccb506
record_format	dspace
spelling	oai:doaj.org-article:8f1ee46cf004453a97ae94b972ccb5062021-11-19T04:11:02ZFrequency of coprescription and potential risk of bronchospasm in Colombian patients users of topical antiglaucomatous betablockers and bronchodilators0121-40042145-2660https://doaj.org/article/8f1ee46cf004453a97ae94b972ccb5062014-07-01T00:00:00Zhttps://revistas.udea.edu.co/index.php/vitae/article/view/15590https://doaj.org/toc/0121-4004https://doaj.org/toc/2145-2660 Background: Cardiovascular and respiratory effects of adrenergic agonists used in diseases like chronic obstructive pulmonary disease (COPD), and β-blockers used in glaucoma generate competitive antagonism on the same adrenergic receptor when used simultaneously with the aggravation that the β-blockers can precipitate bronchospasm. Objective: Determine de frequency of coprescription and potential risk of interaction between bronchodilators and topical antiglaucomatous β-blockers for glaucoma in a database of Colombian patients. Methods: Cross-sectional study in patients older than 40 years treated for bronchial disorders and glaucoma between January 1 and October 31, 2012. We used information about 6.2 million population database of individuals enrolled in Health System of Colombia. In the database it was assessed all prescription records of topical β-blockers and any bronchodilators and the frequency of potential risk of developing drug-induced bronchospasm. The identified patients were informed to the physician responsible to the health attention. Results: We found 1756 patients were receiving topical β-blockers and bronchodilators. Most were women (63.2 %), mean age 73.3 ± 11.1 years, in 61 cities. The antiglaucoma drugs more employees were: timolol (67.5 % of patients), timolol/dorzolamide (18.8 % of patients) and bronchodilators: salbutamol (43.8 % of patients) and ipratropium (41.8 % of patients). The more frequent risk associations of bronchospasm were: salbutamol + timolol (n = 890, 50.6 % of patients), ipratropium bromide + timolol (n = 827, 47.1 %) salbutamol + timolol + dorzolamide (n = 258, 14.6 % of patients) and ipratropium bromide + timolol + dorzolamide (n = 255, 14.5 % of patients). Conclusions: The database research of Negative Outcomes Associated with Medication is useful to know problems in prescription of many therapies. There are potential interactions between antiglaucoma drugs and bronchodilators that increase the risk of precipitating bronchospasm in patients who present asthma, COPD and glaucoma in Colombia. Implementing strategies that link drug dispensers and medical insurers can reduce risks associated with the medication. Jorge Enrique Machado-AlbaValentina Hoyos-SotoUniversidad de AntioquiaarticleglaucomaPulmonary DiseaseChronic ObstructiveBronchial SpasmAdrenergic beta-AntagonistsAdrenergic beta-AgonistsFood processing and manufactureTP368-456Pharmaceutical industryHD9665-9675ENVitae, Vol 21, Iss 2 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	glaucoma Pulmonary Disease Chronic Obstructive Bronchial Spasm Adrenergic beta-Antagonists Adrenergic beta-Agonists Food processing and manufacture TP368-456 Pharmaceutical industry HD9665-9675
spellingShingle	glaucoma Pulmonary Disease Chronic Obstructive Bronchial Spasm Adrenergic beta-Antagonists Adrenergic beta-Agonists Food processing and manufacture TP368-456 Pharmaceutical industry HD9665-9675 Jorge Enrique Machado-Alba Valentina Hoyos-Soto Frequency of coprescription and potential risk of bronchospasm in Colombian patients users of topical antiglaucomatous betablockers and bronchodilators
description	Background: Cardiovascular and respiratory effects of adrenergic agonists used in diseases like chronic obstructive pulmonary disease (COPD), and β-blockers used in glaucoma generate competitive antagonism on the same adrenergic receptor when used simultaneously with the aggravation that the β-blockers can precipitate bronchospasm. Objective: Determine de frequency of coprescription and potential risk of interaction between bronchodilators and topical antiglaucomatous β-blockers for glaucoma in a database of Colombian patients. Methods: Cross-sectional study in patients older than 40 years treated for bronchial disorders and glaucoma between January 1 and October 31, 2012. We used information about 6.2 million population database of individuals enrolled in Health System of Colombia. In the database it was assessed all prescription records of topical β-blockers and any bronchodilators and the frequency of potential risk of developing drug-induced bronchospasm. The identified patients were informed to the physician responsible to the health attention. Results: We found 1756 patients were receiving topical β-blockers and bronchodilators. Most were women (63.2 %), mean age 73.3 ± 11.1 years, in 61 cities. The antiglaucoma drugs more employees were: timolol (67.5 % of patients), timolol/dorzolamide (18.8 % of patients) and bronchodilators: salbutamol (43.8 % of patients) and ipratropium (41.8 % of patients). The more frequent risk associations of bronchospasm were: salbutamol + timolol (n = 890, 50.6 % of patients), ipratropium bromide + timolol (n = 827, 47.1 %) salbutamol + timolol + dorzolamide (n = 258, 14.6 % of patients) and ipratropium bromide + timolol + dorzolamide (n = 255, 14.5 % of patients). Conclusions: The database research of Negative Outcomes Associated with Medication is useful to know problems in prescription of many therapies. There are potential interactions between antiglaucoma drugs and bronchodilators that increase the risk of precipitating bronchospasm in patients who present asthma, COPD and glaucoma in Colombia. Implementing strategies that link drug dispensers and medical insurers can reduce risks associated with the medication.
format	article
author	Jorge Enrique Machado-Alba Valentina Hoyos-Soto
author_facet	Jorge Enrique Machado-Alba Valentina Hoyos-Soto
author_sort	Jorge Enrique Machado-Alba
title	Frequency of coprescription and potential risk of bronchospasm in Colombian patients users of topical antiglaucomatous betablockers and bronchodilators
title_short	Frequency of coprescription and potential risk of bronchospasm in Colombian patients users of topical antiglaucomatous betablockers and bronchodilators
title_full	Frequency of coprescription and potential risk of bronchospasm in Colombian patients users of topical antiglaucomatous betablockers and bronchodilators
title_fullStr	Frequency of coprescription and potential risk of bronchospasm in Colombian patients users of topical antiglaucomatous betablockers and bronchodilators
title_full_unstemmed	Frequency of coprescription and potential risk of bronchospasm in Colombian patients users of topical antiglaucomatous betablockers and bronchodilators
title_sort	frequency of coprescription and potential risk of bronchospasm in colombian patients users of topical antiglaucomatous betablockers and bronchodilators
publisher	Universidad de Antioquia
publishDate	2014
url	https://doaj.org/article/8f1ee46cf004453a97ae94b972ccb506
work_keys_str_mv	AT jorgeenriquemachadoalba frequencyofcoprescriptionandpotentialriskofbronchospasmincolombianpatientsusersoftopicalantiglaucomatousbetablockersandbronchodilators AT valentinahoyossoto frequencyofcoprescriptionandpotentialriskofbronchospasmincolombianpatientsusersoftopicalantiglaucomatousbetablockersandbronchodilators
_version_	1718420507147108352

Frequency of coprescription and potential risk of bronchospasm in Colombian patients users of topical antiglaucomatous betablockers and bronchodilators

Ejemplares similares